Mission Bio has secured equity financing led by Ally Bridge Group to accelerate the commercial adoption of its Tapestri Platform and advance single-cell tri-omics capabilities for precision cancer medicine. The investment comes as the company addresses critical challenges in oncology drug development, where the majority of clinical failures in hematologic cancers occur in Phases II and III due to inadequate patient response and lack of predictive biomarkers.
Revolutionary Single-Cell Multi-Omics Technology
The company recently launched its Single-Cell Genotype and Targeted Gene Expression assay, marking an industry-first capability that enables simultaneous genotype and targeted gene expression profiling from over 10,000 single cells. This breakthrough addresses limitations in existing methods by capturing both genomic mutations and targeted gene expression changes in the same cell, providing pharmaceutical researchers with a comprehensive, high-resolution view of cancer cell behavior and treatment response.
"The majority of clinical failures in hematologic cancer drug development occur in Phases II and III, often due to inadequate patient response and lack of predictive biomarkers for patient stratification," said Brian Kim, CEO of Mission Bio. "We're directly addressing the urgent need to understand which patients will respond to which drugs at what time, by adding this custom capability to our portfolio of tools."
The new assay features sample multiplexing capabilities, reducing the cost of single-cell analysis by approximately 60% compared to using multiple technologies to generate similar insights. The technology has demonstrated value in deconvolving clonal architecture and tracking resistant subclones under therapeutic pressure in acute myeloid leukemia (AML).
Strategic Investment and Commercial Expansion
The funding will support three key initiatives: commercial expansion and partnerships, development of single-cell tri-omics capabilities, and accelerated clinical adoption across multiple cancer segments. Mission Bio plans to broaden its customer reach to support growing demand from pharmaceutical companies developing next-generation cancer therapies.
"This strong support from Ally Bridge Group and other investors validates our leadership position in single-cell multi-omics and enables us to take the next step in our mission of transforming precision medicine," said Kim. "We are now positioned to expand our commercial footprint while advancing our technology to address critical unmet needs in cancer research and treatment."
Kevin Reilly, Managing Director at Ally Bridge Group, emphasized the transformative potential of the technology: "Mission Bio's single-cell tri-omics platform represents exactly the type of transformative life science innovation we seek to support. This investment reflects our continued conviction that Mission Bio's technology will become essential infrastructure for precision medicine, particularly as the industry shifts toward more complex cell and gene therapies requiring comprehensive characterization at the individual cell level."
Clinical Applications and Future Development
The Tapestri Platform's enhanced capabilities will support applications in patient stratification, safety assessments, and therapeutic resistance mechanisms. The company plans to expand clinical utility across multiple cancer segments, including multiple myeloma, myeloid malignancies, and CAR-T cell therapy applications.
Recent clinical validation includes the platform's use as a highly sensitive molecular test to confirm long-term remission for patients with IDH1-mutant AML who received olutasidenib, demonstrating its potential as a high-resolution minimal residual disease (MRD) assay. The technology enables correlation of relapse with complex clonal architecture, surpassing limitations of existing methods like next-generation sequencing or flow cytometry.
Leadership and Platform Innovation
Mission Bio has expanded its leadership team with the appointment of Matthew H. Cato as Chief Commercial Officer. Cato, who has held senior marketing and business development positions with the company since 2017, will help expand the company's commercial leadership in the multi-omics space.
The Tapestri Platform's tri-omics capability will enable simultaneous profiling of DNA, RNA, and protein from single cells, responding to consistent customer demand for integrated genotype and gene expression data. This advancement will help researchers understand mechanisms of action and resistance in cancer therapies while providing comprehensive sample-to-answer solutions for clinicians.
